The beta thalassemia testing market was estimated to be worth USD 445.57 Million in 2022 and is anticipated to grow at a CAGR of 8.2% to reach USD 963.62 Million by 2032.
| Report Attribute | Details |
|---|---|
| Beta Thalassemia Testing Market value (2022) | USD 445.57 Million |
| Beta Thalassemia Testing Market anticipated value (2032) | USD 963.62 Million |
| Beta Thalassemia Testing Market growth rate (2022 to 2032) | 8.2% CAGR |
Beta thalassemia can be simplified as a diseased state of blood in which there is reduced hemoglobin production. Hemoglobin is a protein containing iron and is present in Red blood cells and the major function of hemoglobin is to carry oxygen to the body cells throughout the body.
Low hemoglobin content in the beta thalassemia patients usually leads to the lack of oxygen in many parts of the body. Due to shortage of blood in the body patient, skin becomes pale yellow and the other symptoms like weakness and fatigue are prominent. Risk of abnormal blood clotting highly persist in the patients suffering from beta thalassemia.
According to the symptoms severity the disease can be classified into three thalassemia major (Cooley's anemia), thalassemia intermediate and thalassemia minor. Amongst all the forms of thalassemia, major is considered to be the most dreadful. Diagnostics tests associated with Beta Thalassemia CBC Complete blood Count: CBC determines the amount of hemoglobin and RBC in the blood.
Carriers possess regular hemoglobin level but may have a marginally reduced count of RBC. Patients having more severe type of thalassemia will have a lower RBC and hemoglobin levels. The detection of the diseased state comprises of measuring mean corpuscular volume which is the size of the RBC.
Therefore the mean corpuscular volume is usually found declining in the patients of thalassemia. Hemoglobin tests will show a significant rise in A2 (>2.5%) and a fall in hemoglobin A (<97.5%) for beta thalassemia. Further tests are needed to be performed in patients with decreasing RBC count (anemia), to determine if thalassemia is the cause of the anemia.
To rule out the possibility of iron deficiency anemia iron levels in the blood are checked. DNA testing can also prove as an effective technique for detecting mutation of gene that may cause beta, alpha, or delta thalassemia and also DNA tests verify and confirms other tests, such as blood tests.
Prenatal Genetic testing Thalassemia in fetus can be detected by analyzing the amniotic fluids which is surrounding the fetus. Blood from the developing fetus can also be as good source of sample for detecting thalassemia but aspirating blood sample may cause some damage to a developing fetus, hence taking of amniotic fluid samples is generally preferred.
Chorionic Villus sampling (CVS) is another technique of diagnosing genetic problems in the fetus. Sample is collected from the placental tissue or chorionic villus. There is risk of miscarriage involved with every prenatal test. Preimplantation genetic diagnosis (PGD) is a new procedure that may be performed on embryos which are produced by in vitro fertilization. This test is performed on the embryos which are produced artificially and also allows parents to carry and implant only those embryos that are not carrying the mutated thalassemia genes.
Most commonly prone area for beta thalassemia are Mediterranean countries, African countries, and Southeast Asian countries. Thalassemia trait almost affects 5% to 30% of the population in these ethnic groups. The growing population in these countries act as the drivers for beta thalassemia testing kit market.
A number of factors such as high implementation cost of sophisticated clinical and preclinical imaging systems, High cost of maintenance, low life span of accessories used are restricting the growth of the global imaging market.
The testing market for beta thalassemia has a growing trend in the countries with ethnic groups like, Mediterranean countries, African countries and few countries in Asia Pacific. As migration has become more common, population of beta thalassemia can be seen rising in the developed countries as well.
There are several prenatal test available in the market to determine the possibility of beta thalassemia including both invasive and noninvasive technique. A recent advancement in the testing of beta thalassemia may determine the risk of the disease by in vitro examination of the embryo.
Even though there are many such testing available in the market but lack of awareness leads to the negligence and delayed diagnosis of the diseased state. Approximately 50k – 100k children with β-thalassemia major in middle and low income countries die every year.
The topical regions are more prone to possess high numbers of patients with beta thalassemia like Nigeria, Sudan, Chad, Columbia etc. followed by few South Asian countries. Research Institutes and Pharmaceutical companies, growing usage for beta thalassemia testing and technological advancements, rising awareness are factors driving market growth. Few Asian countries like Myanmar and Thailand also have high number of beta thalassemia patients.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.
The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications. The key players in the in beta thalassemia testing market include Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc Ltd, Tosoh Bioscience, Inc.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for beta thalassemia testing is anticipated to develop significantly throughout the projected period as a result of rising venous disease prevalence and rising new product approvals to meet this demand.
The market is expected to develop as a result of rising disease awareness, the growing value of early detection, and rising spending on chronic illnesses. Beta thalassemia testing products are being used more frequently in both developed and developing nations due to the development of technologically sophisticated products.
An important element driving the market is the rapid uptake of improved technologies for early diagnosis and treatment, which has increased the number of diagnostic tests performed in both private and public laboratories.
To take advantage of the enormous untapped market prospects in the developing world, the market's top companies are concentrating on creating products that are both affordable and of excellent quality. The rising expenditures on R&D and the rising number of new product approvals provide evidence of this.
Beta thalassemia testing products are not widely adopted in poorer countries around the world because of a lack of favourable insurance systems, insufficient knowledge of the disease, high product costs, and poor economic conditions.
The Beta thalassemia testing market participants may benefit from significant growth potential by introducing new, low-cost goods and making more attempts to penetrate these markets.
Principal Consultant
A sizable portion of the market for beta thalassemia testing globally is anticipated to come from North America. The presence of significant market participants and developed healthcare infrastructure in the area is credited with driving the market growth.
The Asia Pacific beta thalassemia testing market is anticipated to grow quickly over the course of the forecast period. Major factors that are predicted to boost the market include increased awareness of the need for early diagnosis and an increase in the number of beta thalassemia cases.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Technology 6.2. Test Type 6.3. Setting 6.4. End-User 7. Global Market Analysis and Forecast, By Technology 7.1. Next-Generation Sequencing 7.2. Polymerase Chain Reaction 7.3. Others 8. Global Market Analysis and Forecast, By Test Type 8.1. Prenatal Testing 8.2. Genetic Testing 8.3. Others 9. Global Market Analysis and Forecast, By Setting 9.1. Laboratories 9.2. Point of Care 10. Global Market Analysis and Forecast, By End-User 10.1. Hospitals & Clinics 10.2. Clinical Laboratories 10.3. Others 11. Global Market Analysis and Forecast, By Region 11.1. North America 11.2. Latin America 11.3. Western Europe 11.4. Eastern Europe 11.5. Asia Pacific 11.6. Japan 11.7. Middle East and Africa 12. North America Sales Analysis and Forecast, by Key Segments and Countries 13. Latin America Sales Analysis and Forecast, by Key Segments and Countries 14. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 15. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries 16. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 17. Japan Sales Analysis and Forecast, by Key Segments and Countries 18. Middle East and Africa Sales Analysis and Forecast, by Key Segments and Countries 19. Sales Forecast by Technology, Test Type, Setting, and End-User for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 21. Company Profile 21.1. MedGenome 21.2. TRUPCR 21.3. Bio-Rad Laboratories, Inc. 21.4. ViennaLab Diagnostics GmbH 21.5. Thermo Fisher Scientific Inc. 21.6. PerkinElmer Inc 21.7. Asper Biogene 21.8. BGI 21.9. Tosoh Bioscience, Inc. 21.10. Mapmygenome
Explore Healthcare Insights
View Reports
Beta Thalassemia Testing Market
